Navigation Links
Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results
Date:1/23/2010

SCOTTSDALE, Ariz., Jan. 22 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company, announced today that financial results for the fiscal 2010 third quarter, ended December 31, 2009, will be released after the market closes on Monday, January 25, 2010. An earnings conference call will be held the following morning on Tuesday, January 26, 2010 at 11:00 AM ET.

To access the teleconference, please call (888) 452-4006 (domestic) or (719) 457-2602 (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at (888) 203-1112 (domestic) or (719) 457-0820 (international), replay code 2094143 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. ( MTXX), visit our website at www.matrixxinc.com.  For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Treasurer, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

SOURCE Matrixx Initiatives, Inc.

RELATED LINKS
http://www.matrixxinc.com

'/>"/>

SOURCE Matrixx Initiatives, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
2. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
3. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
6. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
7. Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up
8. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
9. HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008
10. Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results
11. Patient Safety Technologies Reports Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Cirujanos holandeses han puesto en marcha una ... compartir sus mejores prácticas por el mundo y tratar ... Europa, África, Asia y Estados ... combina la transmisión en vivo con mensajería instantánea y ... "Imagine un médico de Medicines sans Frontieres ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology:
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 , ... ... by inspiring human interest stories, which come courtesy of leaders in the nursing and ... the industry, from leading advocates and associations—namely Abilene Christian University. , As the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... There are ... Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off ... 63 percent say grilling is their favorite way to cook a hot dog, far ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia ... to its specialty academic programs. , Answering to the increasing demand for curricular ... in health law, and environmental and land use law. ,  , “The demand ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... Hereditary Retinal Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June ... to the public. , Dr. Maisel, founder of Retina Group of New ...
Breaking Medicine News(10 mins):